FDA said this week that it is restricting the use of codeine and tramadol medicines in children. The drug’s labels will now include a contraindication that codeine should not be used to treat pain or cough, and that tramadol should not be used to treat pain, in children younger than 12 years.
A new Commonwealth Fund survey on how Medicaid changes could affect this population, has experts weighing in on ways to resolve the healthcare disconnect.
Our policy analyst explains the concept of invisible high-risk pools, and explains how they might affect health reform.
Decades of research has led to a flurry of new warnings.
To date, the CDC reports 5,234 Zika virus disease cases in the United States and 36,526 cases in U.S. territories. Here’s where we are in the vaccine development process.
National survey and surveys in New York State, Florida, Texas, and New Hampshire point to a need for more actionable price information.
Nationwide Children’s Hospital sees dramatic drop in ED visits and inpatient admissions for epilepsy patients with collaborative quality improvement project.
Citing safety concerns, FDA delayed approval of a new blockbuster drug to treat rheumatoid arthritis.
Population health data strategies are finding connections between better health and better quality of living.
A hospital system is adapting population health data to create a blueprint for a cost savings patient care program.
A new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%.
This novel approach aims to help those already struggling with obesity and diabetes, but eventually win the fight against this epidemic.
CVS, Novo Nordisk launch a prescription savings program to help patients afford essential medications.
One thing that is unlikely to change under the new Administration is the goal of reducing the cost of healthcare through various alternative payment initiatives. Here’s how that will affect oncology.
The call for antimicrobial stewardship is growing. Enact these steps to prevent a return to the pre-antibiotic era.
Blue Cross Blue Shield of Illinois partners with gastroenterology group to focus on Crohn’s disease patients.
With a growing need for services, nearly nine in 10 employers cite behavioral health as an important priority in Willis Towers Watson survey.
Two studies, one from Prime Therapeutics and Stanford, reveal an alarming increase in overdose with concurrent use of opioids and benzodiazepines. Here’s how managed care can help.
Industry leaders say that despite criticisms against the healthcare industry, there are some great lessons it can teach other industries.
FDA approved supplemental applications for 2 primary hepatitis C medications to be used in children for the first time.
Two recent studies demonstrate that pirfenidone (Esbriet, Genentech) prolongs life expectancy by 2.47 years for IPF patients and that Esbriet and nintedanib (Ofev, Boehringer Ingelheim) reduce the decline in lung function.
FDA recently approved deutetrabenazine (Austedo, Teva Pharmaceuticals) to treat chorea associated with Huntington’s disease (HD). The medication is only the second product approved to treat HD, and is the first deuterated product approved by FDA.
The healthcare industry continues to focus efforts on treatments that work better, and ideally are less expensive and less invasive for patients.
The healthcare industry continues to focus efforts on treatments that work better, and ideally are less expensive and less invasive for patients.
Getting diabetic patients to adhere to medication and dietary changes can be difficult. Here are some tips from experts.
Polypharmacy presents real problems-especially for older adults.
These trends emerge from CDW’s Patient Engagement Perspective Study, but surprisingly one tech trend didn’t make the cut.
What exactly did House representatives on both sides of the aisle dislike about the AHCA? Here’s a look at what MCOs should know.
Could new technology solve America’s diabetes crisis? Find out.
While FDA just approved the first drug for primary progressive multiple sclerosis (PPMS), the drug’s price tag is controversial.
